Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic effect of baricitinib in lichen planopilaris
IRCT20221101056374N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Dec 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of baricitinib in lichen planopilaris (LPP), sponsored by Tehran University of Medical Sciences. Started Dec 2022; status: completed.
02
Drugs
baricitinib
03
Conditions
lichen planopilaris (LPP)
Beyond the preview
Go deeper on IRCT20221101056374N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221101056374N1.